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Introduction
Griscelli syndrome was first described by Griscelli and 
Siccardi in 1978 in a hospital in Paris.1  It is a rare autosomal 
recessive disorder resulting in pigmentary dilution of the skin 
and hair, presence of large clumps of pigment in hair shafts and 
an accumulation of melanosomes in melanocytes.2 It results in 
silver-grey hair along with variable cellular immunodeficiency 
or severe neurological impairment or both.2 The condition is 
rare in all countries and up to January 2003 only 60 cases had 
been described in the world medical literature 2.  In most cases 
diagnosis occurs between the ages of 4 months to 7 years.2
The boy discussed here had silvery hair, eyebrows and 
eyelashes (Figure 1) and was admitted at the age of five months to 
hospital with fever, hepatosplenomegaly and pancytopaenia. 
Case Report
A 5-month old Maltese boy, MS, was referred to our centre 
with a two-day history of fever and irritability. From birth he 
was noted to have silver grey (leaden) hair and silvery grey 
eyebrows and eyelashes.  His parents were unrelated and MS 
was their only child. The physical examination revealed pallor, 
hepatomegaly and splenomegaly. The boy was thriving (wt: 
7.9kg, P50) and his development was normal. The neurological 
examination was unremarkable.
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The initial investigations showed pancytopaenia, but 
there were no abnormal cells in the peripheral blood (Table 
1). Biochemical tests of liver function showed moderately 
raised bilirubin and liver enzymes and the blood coagulation 
was abnormal with a raised INR and APTT (Table 1). Broad-
spectrum antibiotics (piptazobactam and gentamicin) were 
started because of fever and neutropaenia and MS was given a 
platelet and a blood transfusion.
Blood cultures and tests for EBV, CMV, visceral leishmanisis 
and brucellosis were negative. The bone marrow showed 
abundant macrophages and ineffective erythropoiesis, whilst 
the CSF was normal. A raised serum triglyceride, LDH, serum 
ferritin and a low serum fibrinogen (Table 1) supported the 
diagnosis of haemophagocytic lymphohistiocytosis. Further 
evidence of HLH was given by lymphocyte subset studies that 
typically showed low Suppressor/Cytotoxic T lymphocytes, 
a raised Helper/Suppressor index and low Natural Killer T 
lymphocytes (Table 1). 
Magnetic resonance imaging of the brain was completely 
normal and did not show any white matter infiltration or 
abnormality.  Microscopic examination of MS’s hair shafts 
showed large discrete clumps of melanin pigment along the 
length of the shaft and this was consistent with the Griscelli 
syndrome. 
Figure 1: MS with the typical pigmentary defect of the 
Griscelli syndrome. Note the silvery (leaden) hair and 
eyebrows. These changes are usually present at birth and 
should alert the physician of the possibility of the Griscelli 
syndrome.
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Treatment according to the HLH-94 protocol, an international 
study co-ordinated by the Histiocyte Society for the treatment 
of Haemophagocytic Lymphohistiocytosis 3, was commenced. 
The induction phase consisted of twice weekly etoposide for six 
weeks and oral dexamethasone for eight weeks. This resulted in 
resolution of the hepatosplenomegaly and the pancytopaenia, 
with reversal of the LDH, fibrinogen and triglyceride levels to 
normal. Remission was maintained with daily cyclosporin A and 
etoposide/dexamethasone every fortnight.
Curative treatment for the Griscelli syndrome (accelerated 
phase) involves a stem cell transplant and since MS had no 
siblings an international search for an unrelated donor was 
commenced.  The best available donor was that from the Italian 
cord blood panel and the donor was a 9/10 HLA match with our 
patient. A mismatched unrelated cord transplant was carried 
out at Great Ormond Street Hospital in London. Unfortunately 
the transplant was not successful and a second procedure was 
planned for October 2005.
Discussion
This is the first time that a case of Griscelli syndrome is 
described in the Maltese medical literature and this case serves 
to highlight the salient features of the disease. Although Griscelli 
syndrome is a very rare condition the silvery grey (leaden) hair, 
eyebrows and eyelashes (Figure 1) are very characteristic and 
should alert the physician to the possibility of the syndrome. 
Griscelli and Siccardi first described the Griscelli syndrome 
in 1978.1 It is an autosomal recessive disorder resulting in 
pigmentary dilution of the skin and hair with the presence 
of large clumps of pigment in hair shafts as a result of 
the accumulation of melanosomes in melanocytes.2 More 
significantly the inherited metabolic defect can also be 
associated with haemophagocytic lymphohistiocytosis and/or 
severe neurological impairment early in life. 
Our patient presented with the pigment disorder and immune 
dysfunction resulting in partial albinism and haemophagocytic 
lymphohistiocytosis. In most cases diagnosis is made between 
the ages of 4 months to 7 years.2
Three main types of Griscelli syndrome are recognized and 
classified according to the mutation involved and the clinical 
presentation. The common pigmentary defect observed in 
the three types (GS1, GS2 and GS3) results from the absolute 
requirement and interaction of three encoded proteins for 
melanosome transport.  GS1 associates characteristic albinism 
with a severe primary neurological impairment. Patients exhibit 
severe developmental delay and mental retardation occurring 
early in life. These patients carry mutations of the myosin 5A gene 
(MYO5A), which encodes an organelle motor protein, Myosin 
5A (MyoVa), and has a determining role in neuron function.4, 5 
The second type of Griscelli syndrome (GS2) is characterized 
by the same hypopigmentation associated with an immune 
defect, leading to episodes of life-threatening uncontrolled T 
lymphocyte and macrophage activation that are the hallmark 
of haemophagocytic lymphohistiocytosis (HLH).6 During HLH 
activated T cells and macrophages infiltrate various organs 
(including the brain), leading to massive tissue damage, organ 
failure, and death in the absence of treatment.6 The immune 
dysfunction can initially be controlled with immunosuppressive 
treatment but haematopoietic stem cell transplantation is the 
only definitive curative treatment for this condition.6 Mutations 
in RAB27A, a gene that encodes a small GTPase protein (Rab27a) 
and is involved in the function of the intracellular-regulated 
secretory pathway, cause GS2.7 The immune deregulation 
observed in GS2 patients is accounted for by the absolute 
requirement of the Rab27a protein function for lymphocyte 
cytotoxic granule release and underlines the determining role 
of this cytotoxic pathway in immune homeostasis.7 Therefore in 
GS2 patients the ability of lymphocytes and natural killer cells to 
lyse target cells is impaired or absent due to a consistent inability 
to secrete cytotoxic granules. This inherited defect therefore 
accounts for the severe immunologic disorder characteristic of 
this syndrome, namely haemophagocytic lymphohistiocytosis. 
Both genes (MYO5A and RAB27A) map to the same chromosome 
15q21.1 region and are distant from each other by less than 1.6 
cM.8 Homozygous missense mutation in human melanophilin 
(MLPH), leading to defective Rab27a – Mlph interaction, 
results in a third form of GS (GS3), the phenotype of which is 
restricted to hypopigmentation only.9 Slac2/melanophilin is the 
link between myosin Va and GTP-Rab27a. In the absence of the 
tripartite protein complex (Rab27a-Mlph-MyoVa) formation in 
melanocytes, melanosomes cannot be connected to the actin 
network and thus transported toward the melanocytes tips 
(Figure 2).9, 10 Our patient, MS, probably has the GS2 form of 
Griscelli syndrome and the genetic studies done while the patient 
was in London are awaited.
The main differential diagnoses in our patient were the 
Chediak-Higashi syndrome (CHS) and Elejalde syndrome (ES). 
Both disorders can present with the characteristic silvery grey 
Haemoglobin 7.8g/dl
White blood cell count 7.3    x  10 9 /l
Neutrophil count 0.79  x  10 9 /l
Platelets 32 x 10 9 /l
Bilirubin 32 µmol/l
INR 1.4
APTT ratio 74s
Fibrinogen  0.83g/l (n.v. 2-4g/l)
Serum triglycerides 5.7mmol/l (n.v. 0.4–2.3)
Serum LDH 908U/l (n.v. <425)
Serum ferritin 1279 ng/ml (n.v. 28 – 365)
Total lymphocyte count 1501 Val/uL
Suppressor/Cytotoxic 
 T cell count 143 Val/ul 
Helper/Suppressor Index 
 (CD4/CD8) 3.1 (n.v. 0.5 – 2.6)
Natural Killer T Cells 0.8% of the total lymphocyte
  count (n.v. 2- 25%)
Table 1: Initial blood investigations 
Malta Medical Journal    Volume 18   Issue 02   July 2006 2
Figure 2: Scheme of the heterotrimeric protein complex 
involved in human melanosome transport. A defect in any 
of the proteins, MyoVa, Rab27a, or Mlph, leads to identical 
pigmentary dilution, found in the three forms of GS. The F-
exon on MyoVa is required for MyoVa-Mlph interaction and 
the SHD of Mlph for Mlph-Rab27a interaction.10
(leaden) hair, eyebrows and eyelashes seen in our patient. In CHS 
the patients exhibit hypopigmentation of the skin, eyes and hair, 
prolonged bleeding times, easy bruisability, recurrent infections, 
abnormal killer cell function and peripheral neuropathy.11 
The hallmark of CHS is the presence of giant intracytoplamic 
granules in virtually all granulated cells, which is never observed 
in GS.11 In CHS, defective melanosome transfer is secondary to 
a primary defect in a protein called LYST (lysosome trafficking 
regulator).12 This is a membrane-associated molecule that is 
important in protein docking and fusion and for membrane 
stability of certain organelles.12 Therefore the basic defect in 
CHS results in the defective formation of giant melanosomes 
that are consequently difficult to transfer to keratinocytes. 
In GS, on the other hand, mature melanosomes are formed 
normally but it is the tripartite protein complex of Rab27a-
Mlph-MyoVa (the transfer mechanism) that is defective. Elejalde 
syndrome15 main features include silvery hair, intense tanning 
after sun exposure, severe neurological impairment and a wide 
spectrum of ophthalmological abnormalities.13 The neurological 
impairment can be congenital or develops during childhood and 
includes seizures, severe hypotonia and mental retardation.13 ES 
does not involve impairment of the immune system and appears 
related to or allelic to GS1, and thus associated with mutations 
in MYOVA. However its gene mutation has yet to be defined.14 
Like the Griscelli syndrome, both CHS and ES are inherited in 
an autosomal recessive way and therefore carry a recurrence 
risk of 1 in 4 for the index family.
Our patient, MS, presented with the characteristic 
phenotype of GS2 including the silvery grey hair and evidence 
of haemophagocytic lymphohistiocytosis (HLH). HLH is a 
Class II Histiocytosis or Non Langerhan Cell Histiocytosis 
and it can be secondary (e.g. infection associated) or primary 
(familial). Familial Haemophagocytic Lymphohistiocytosis 
(FHL 1-3) results from mutations of the perforin (FHL2)15, 
Munc13-4 (FHL3)16 and a yet unidentified gene mapped 
to human chromosome 9q21 (FHL1) 17. A number of other 
conditions with an inherited metabolic defect that can lead 
to HLH have been described and Griscelli syndrome type 2 
and Chediak-Higashi syndrome are good examples of these 
conditions.  The most typical clinical findings of HLH are fever, 
hepatosplenomegaly, anaemia and bruising. Some patients 
present with neurological symptoms, lymphadenopathy, 
rash, jaundice and oedema. Common laboratory findings are 
pancytopaenia, hypertriglyceridaemia, hypofibrinogenaemia, 
coagulopathy and liver dysfunction. Other abnormal laboratory 
findings are low natural killer cell activity, hypercytokinaemia 
and a high serum ferritin and lactate dehydrogenase. Most 
of these abnormalities, except for central nervous system 
involvement, were found in our patient MS. 
An important clue to the diagnosis of the Griscelli syndrome 
is from the histological examination of the hair shaft of the 
patient. Examination of the hair shaft from our patient showed 
large discreet clumps of melanin pigment along the length of 
the shaft, instead of the homogeneous distribution of small 
pigment granules seen in normal hair.18 In Chediak-Higashi 
syndrome, the hair shaft also contains a typical pattern of uneven 
accumulation of large pigment granules but in GS the clusters 
of melanin pigment on the hair shaft are six times larger than 
in CHS.18
Our patient, MS, is at present in the United Kingdom 
awaiting a second haematopoietic stem cell transplant (HSCT). 
A HSCT from a histocompatible donor offers the best chances 
of long-term survival for Griscelli syndrome patients with 
HLH.19 Durable long=term remissions can be achieved with 
chemotherapy and cyclosporin A, and neuro-cerebral disease can 
also be controlled transiently with intrathecal methotrexate.20 
Patients will need aggressive support and monitoring during the 
course of their illness similar to patients having chemotherapy 
for oncological conditions.  However, the prognosis for long term 
survival of patients with Griscelli Syndrome and HLH is poor 
for those patients who do not have a histocompatible donor or 
who relapse after a HSCT.
Conclusion 
We present the first documented case of the Griscelli 
syndrome in a Maltese patient. The characteristic phenotypic 
appearance, especially the pigment disorder of the patient’s 
hair, is emphasized so that it is quite possible to suspect the 
diagnosis at the bedside. The underlying defects of the condition 
are also presented and these serve to shed important light on 
the importance of the secretory pathways required for normal 
lymphocyte cytotoxicity, melanosome transfer and neuro-
synaptic transmission.
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